Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, August 4, 2023
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
Thursday, July 20, 2023
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Wednesday, July 12, 2023
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
Friday, July 7, 2023
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Friday, June 30, 2023
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced
Thursday, June 22, 2023
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City
Monday, June 12, 2023
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Thursday, June 8, 2023
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
Friday, June 2, 2023
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
Friday, May 26, 2023
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: